Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a)
https://doi.org/10.14412/2074-2711-2022-1S-34-37
Abstract
Patient adherence to therapy with multiple sclerosis disease-modifying treatments (MS DMTs) in many cases determine the effectiveness of therapy. The review discusses the reasons for low adherence to DMTs, ways to increase it. Among the most effective ways is to reduce the frequency of administration of the drug while maintaining its high efficiency. To illustrate this, the increase in adherence to treatment with interferon-β drugs due to pegylation is discussed. Without losing its effectiveness, sampeginterferon beta-1a (samPEG-IFN-β1a) administration reduces the frequency of local adverse reactions, partly due to reducing the frequency of injections, which contributes to higher adherence to the treatment.
Keywords
multiple sclerosis,
treatment,
multiple sclerosis disease-modifying treatments,
adherence to therapy,
sampeginterferon
Supporting agencies: This article has been supported by Biocad.
About the Author
A. N. Boyko
Department of Neurology, Neurosurgery and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Institute of Clinical Neurology, Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Alexey Nikolaevich Boyko
1, Ostrovityanova St., Moscow 117997
1, Ostrovityanova St., Build. 10, Moscow 117997
References
1. Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler. 2008 Jan;14(1):94-105. doi: 10.1177/1352458507079658. Epub 2007 Sep 19.
2. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59(3-4):131-5. doi: 10.1159/000111875. Epub 2007 Nov 30.
3. O'Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005 Feb;11(1):46-50. doi: 10.1191/1352458505ms1131oa
4. Сидоренко ТВ, Бойко АН, Гусев ЕИ. Приверженность к длительному лечению препаратами, изменяющими течение рассеянного склероза (ПИТРС). Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2009;109(7-2):107-13. [Sidorenko TV, Boyko AN, Gusev EI. Adherence to long-term treatment with drugs that change the course of multiple sclerosis (DMTs). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2009;109(7-2):107-13 (In Russ.)].
5. Попова ЕВ, Новикова КВ, Хачанова НВ и др. Поиск оптимальной патогенетической терапии рассеянного склероза: возможность повысить приверженность больных терапии, не снижая ее эффективности. Журнал неврологии и психиатрии им. С.С. Корсакова 2017;117(10-2):48-52. doi: 10.17116/jnevro 201711710248-52 [Popova EV, Novikova KV, Khachanova NV, et al. The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(10-2):48-52. doi: 10.17116/jnevro201711710248-52 (In Russ.)].
6. Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. Jan-Feb 2013;19(1 Suppl A):S24-40. doi: 10.18553/jmcp.2013.19.s1.S24
7. Boyko AN. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence. Expert Opin Biol Ther. 2010 Apr;10(4): 653-66. doi: 10.1517/14712591003702361
8. Cutter G, Veneziano A, Grinspan A, et al. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Mult Scler Relat Disord. 2019 Aug;33:13-21. doi: 10.1016/j.msard.2019.04.036. Epub 2019 May 9.
9. Cutter G, Veneziano A, Grinspan A, et al. Satisfaction and Adherence With Glatiramer Acetate 40 mg/mL TIW in RRMS After 12 Months, and the Effect of Switching From 20 mg/mL. Mult Scler Relat Disord. 2020 May;40:101957. doi: 10.1016/j.msard.2020.101957. Epub 2020 Jan 20.
10. Di Battista G, Bertolotto A, Gasperini C, et al. Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided Quality. Mult Scler Int. 2014;2014:752318. doi: 10.1155/2014/752318. Epub 2014 Aug 26.
11. Freidel M, Ortler S, Fuchs A, et al. Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore study. Neurosci Nurs. 2015 Feb;47(1):E31-9. doi: 10.1097/JNN.0000000000000100
12. DuChane J, Clark B, Staskon F, et al. Walgreens connected care: impact of managed therapy on adherence to medications used to treat multiple sclerosis and related comorbid conditions. Int J MS Care. Mar-Apr 2015; 17(2):57-64. doi: 10.7224/1537-2073.2013-051
13. Yermakov S, Davis M, Calnan M, et al. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J Med Econ. 2015;18(9):711-20. doi: 10.3111/13696998.2015.1044276. Epub 2015 Jun 1.
14. Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005 Sep;252 Suppl 3:iii3-iii9. doi: 10.1007/s00415-005-2010-6
15. Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update. Biologics. 2013;7:131-8. doi: 10.2147/BTT.S29948. Epub 2013 May 29.
16. Tolley K, Hutchinson M, You X, et al. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of RelapsingRemitting Multiple Sclerosis. PLoS One. 2015 Jun 3;10(6):e0127960. doi: 10.1371/journal.pone.0127960
17. Мельников МВ, Касаткин ДС, Волков АИ, Бойко АН. Пегилированная форма интерферона бета в терапии рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(8):136-41. doi: 10.17116/jnevro2019119081136 [Melnikov MV, Kasatkin DS, Volkov AI, Boyko AN. The pegylated form of interferon beta in the treatment of multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(8):136-41. doi: 10.17116/jnevro2019119081136 (In Russ.)].
18. Бойко АН, Бахтиярова КЗ, Дудин ВА и др. Новый пегилированный интерферон бета-1а (сампэгинтерферон бета-1а, BCD-054) в терапии ремиттирующего рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10):100-9. doi: 10.17116/jnevro2019119102100 [Boyko AN, Bakhtiyarova KZ, Dudin VA, et al. The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(10):100-9. doi: 10.17116/jnevro201911910100 (In Russ.)].
19. Бойко АН, Бойко ОВ, Бахтиярова КЗ и др. Эффективность и безопасность сампэгинтерферона β-1а для лечения ремиттирующего рассеянного склероза: результаты 52-недельного рандомизированного двойного слепого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1):62-71. doi: 10.17116/jnevro 202212201162 [Boyko AN, Boyko OV, Bakhtiyarova KZ, et al. Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162 (In Russ.)].
20. Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018;11:1756286418791143. doi: 10.1177/1756286418791143
Review
For citations:
Boyko A.N. Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a). Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1S):34-37. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1S-34-37
Views: 194
Email this article 